Literature DB >> 8695040

Effect of pergolide on endogenous and exogenous L-DOPA metabolism in the rat striatum: a microdialysis study.

S Dethy1, M A Laute, A Luxen, J Hildebrand, S Goldman.   

Abstract

We used a model of intrastriatal microdialysis in freely moving rats to study the effect of pergolide, a mixed D1/D2 dopamine (DA) receptor agonist with predominant D2 action in vivo, on the biotransformation of endogenous and exogenous L-DOPA. Levels of L-DOPA, DA, DOPAC, HVA and 5-HIAA were measured by high performance liquid chromatography. Pergolide (50 micrograms/kg, i.p.) caused a 47%, 65% and 70% decrease in basal striatal extracellular (EC) levels of DOPAC, HVA and DA, respectively. L-DOPA (100 mg/kg, i.p.), injected 2 hours after carbidopa, produced significant increase in EC levels of L-DOPA, DOPAC, HVA and DA in rats with and without local perfusion of 10(-4) M pergolide. The DOPAC peak value was lower and was reached 60 minutes later in the group with pergolide. This study demonstrated inhibitory effects of pergolide on endogenous DA release and influence of pergolide on exogenous L-DOPA biotransformation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8695040     DOI: 10.1007/bf01271541

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  26 in total

1.  Importance of the calcium content infused during microdialysis for the effects induced by D2 agonists on the release of dopamine in the striatum of the rat.

Authors:  W Timmerman; B H Westerink
Journal:  Neurosci Lett       Date:  1991-09-30       Impact factor: 3.046

2.  Effects of (8beta)-8-[methylthio)methyl]-6-propylergoline on dopaminergic function and brain dopamine turnover in rats.

Authors:  R W Fuller; J A Clemens; E C Kornfeld; H D Snoddy; E B Smalstig; N J Bach
Journal:  Life Sci       Date:  1979-01-22       Impact factor: 5.037

3.  Long-term study of pergolide in Parkinson's disease.

Authors:  J Jankovic
Journal:  Neurology       Date:  1985-03       Impact factor: 9.910

4.  In vivo assessment of release and metabolism of dopamine in the ventrolateral striatum of awake rats following administration of dopamine D1 and D2 receptor agonists and antagonists.

Authors:  R E See; B A Sorg; M A Chapman; P W Kalivas
Journal:  Neuropharmacology       Date:  1991-12       Impact factor: 5.250

5.  Modified microdialysis probe for sampling extracellular fluid and administering drugs in vivo.

Authors:  G Yadid; K Pacak; I J Kopin; D S Goldstein
Journal:  Am J Physiol       Date:  1993-11

6.  Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats.

Authors:  E D Abercrombie; A E Bonatz; M J Zigmond
Journal:  Brain Res       Date:  1990-08-13       Impact factor: 3.252

7.  Regulation of striatal aromatic L-amino acid decarboxylase: effects of blockade or activation of dopamine receptors.

Authors:  M Y Zhu; A V Juorio; I A Paterson; A A Boulton
Journal:  Eur J Pharmacol       Date:  1993-07-20       Impact factor: 4.432

8.  Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats.

Authors:  D L Felten; S Y Felten; R W Fuller; T D Romano; E B Smalstig; D T Wong; J A Clemens
Journal:  Neurobiol Aging       Date:  1992 Mar-Apr       Impact factor: 4.673

9.  Low and high dose bromocriptine have different effects on striatal dopamine release: an in vivo study.

Authors:  T Brannan; J Martínez-Tica; A Di Rocco; M D Yahr
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1993

10.  Biphasic effect of locally applied apomorphine and 2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine on the release of striatal dopamine investigated by means of brain dialysis.

Authors:  K Kurata; R Shibata
Journal:  Neurosci Lett       Date:  1990-09-18       Impact factor: 3.046

View more
  1 in total

Review 1.  Access to the CNS: Biomarker Strategies for Dopaminergic Treatments.

Authors:  Willem Johan van den Brink; Semra Palic; Isabelle Köhler; Elizabeth Cunera Maria de Lange
Journal:  Pharm Res       Date:  2018-02-15       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.